Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Hodsman
Anthony
A
Division of Nephrology, University of Western Ontario and St. Joseph's Health Centre, London, Ont. anthony.hodsman@sjhc.london.on.ca
Papaioannou
Alexandra
A
Ann Cranney
D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012196:Review Literature as Topic; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone; D019379:Teriparatide